Bio-AMS (TFA) is a potent bacterial biotin protein ligase inhibitor. Bio-AMS (TFA) possesses selective activity against Mycobacterium tuberculosis (Mtb) and arrests fatty acid and lipid biosynthesis[1].
Bio-AMS possesses excellent antitubercular activity against Mtb H37Rv and MDR/XDR-TB strains with MICs ranging from 0.16 to 0.625 μM and is not affected by changes to the primary carbon source[1].
Bio-AMS (2.5, 5 and 10 μM; 24 h) inhibits growth of Mtb in a concentration-dependent manner in Mtb-infected mouse macrophages; shows no signs of mitochondrial toxicity[2].
[1]. Bockman MR, Aldrich CC, et al. Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification. ACS Infect Dis. 2018 Jul 13;4(7):1102-1113.
[2]. Tiwari D, Schnappinger D, et al. Targeting protein biotinylation enhances tuberculosis chemotherapy. Sci Transl Med. 2018 Apr 25;10(438):eaal1803.